# NeuroLambda Therapeutics, Inc. — Form D

NeuroLambda Therapeutics, Inc. of Cambridge, MA, a company, filed a Form D exempt-offering notice with the SEC on 2024-07-17. The offering totals $5.0M, of which $3.0M was reported sold. Industry: Other Technology.

## Offering

- Filed: 2024-07-17
- Form: D
- Accession: 0002029691-24-000002
- Industry: Other Technology
- Exemptions: 06b
- Total offering: $5.0M
- Amount sold: $3.0M
- Remaining: $2.0M
- Investors: 1
- Date of first sale: 2024-06-21
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-519102

## Issuer

- Name: NeuroLambda Therapeutics, Inc.
- CIK: 0002029691
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2023
- Address: 1 Broadway, 14th Floor, Cambridge, MA, 02142
- Phone: 929-375-5755

## Officers, directors & promoters (4)

| Name | Role | Location |
| --- | --- | --- |
| Xiaowei Jin | Director | Cambridge, MA |
| Byungchan Kim | Director | Cambridge, MA |
| Sayan Mondal | Director | Cambridge, MA |
| Sayan Mondal | Executive Officer | Cambridge, MA |

## More

- [CIK 2029691 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2029691&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0002029691-24-000002.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.